779 related articles for article (PubMed ID: 32211776)
1. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
2. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
3. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
[TBL] [Abstract][Full Text] [Related]
4. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
6. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
[TBL] [Abstract][Full Text] [Related]
7. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
8. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
9. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
10. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
11. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
13. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
14. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
16. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridi M; Hadziyannis E; Berby F; Zachou K; Testoni B; Rigopoulou E; Gatselis NK; Lyberopoulou A; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Papatheodoridis GV
J Viral Hepat; 2020 Feb; 27(2):118-126. PubMed ID: 31562748
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
[TBL] [Abstract][Full Text] [Related]
19. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
[TBL] [Abstract][Full Text] [Related]
20. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
